Minhai COVID-19 vaccine (Chinese: 康泰民海新冠疫苗), trademarked as KCONVAC (Chinese: 可维克; pinyin: Kěwéikè), is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Other names | KCONVAC (Chinese: 可维克; pinyin: Kěwéikè) |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
In October 2020, KCONVAC started phase I clinical trials with 180 participants in China.[1] Later, KCONVAC started phase II trials with 1,000 participants in China.[2]
In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.[3]
In August 2021, KCONVAC started phase I trials with 84 participants in China.[4]
In September, KCONVAC started phase II trials with 480 participants in China.[5]
On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.[6]